Litigation Details for SUPERNUS PHARMACEUTICALS, INC. v. RICONPHARMA LLC (D.N.J. 2021)
✉ Email this page to a colleague
SUPERNUS PHARMACEUTICALS, INC. v. RICONPHARMA LLC (D.N.J. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-06-03 |
| Court | District Court, D. New Jersey | Date Terminated | 2023-08-21 |
| Cause | 35:271 Patent Infringement | Assigned To | Michael E. Farbiarz |
| Jury Demand | None | Referred To | Michael A. Hammer |
| Patents | 10,220,042; 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in SUPERNUS PHARMACEUTICALS, INC. v. RICONPHARMA LLC
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for SUPERNUS PHARMACEUTICALS, INC. v. RICONPHARMA LLC (D.N.J. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-10-28 | 102 | Opinion | the ’975 patent”), 9,370,525 (“the ’525 patent”), 9,855,278 (“the ’278 patent”), and 10,220,042 (“the … The patents-in-suit are Patent Nos. 7,722,898 (“the ’898 patent”), 7,910,131 (“the ’131 patent”), 8,…,600 (“the ’600 patent”), 8,821,930 (“the ’930 patent”), 9,119,791 (“the ’791 patent”), 9,351,975 (“the…Supernus’s complaint for patent infringement (DE 1) ’898 Patent = Patent No. 7,722,898 (DE 80-2)…the ’042 patent”). These patents describe a formulation for an extended- release oxcarbazepine tablet used | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
